Switch to optionsXpress for advanced derivatives trading & earn 50 commission-free trades.
Advertisement
SureTrader Stock Hero Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator mick, Foxwoods Man, drkazmd65, maverick1856
Search This Board:
Last Post: 3/26/2015 7:12:11 PM - Followers: 161 - Board type: Free - Posts Today: 8

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/



Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
  2. The scientific, clinical, and commercial development of the medicine and
  3. CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  
  2. Teva Pharmaceuticals Industries Ltd.
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  
  3.  
  4. Orient Europharma Co. Ltd.
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  
  5.  
  6. IDC-GP Pharm LLC 
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  
  7.  

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
Wiki
CVM News: Current Report Filing (8-k) 03/18/2015 04:31:20 PM
CVM News: CEL-SCI Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial 03/03/2015 08:15:00 AM
CVM News: CEL-SCI Completes Key Milestone with Clearance to Conduct Phase III Trial in 21 Countries 02/27/2015 03:22:00 PM
CVM News: FinancialBuzz.com Exclusive Interview With CEL-SCI CEO Geert Kersten From the Floor of the NYSE 02/23/2015 09:00:00 AM
CVM News: CEL-SCI To Participate in Ascendiant’s Quarterly Management Discussion Series Today, Friday February 20 at 11 Am Eastern Time 02/20/2015 08:00:00 AM
PostSubject
#6818  Sticky Note CEL-SCI (NYSE: CVM) is the most undervalued Phase maverick1856 02/27/15 01:26:17 PM
#6737  Sticky Note And then there were 20,.... drkazmd65 02/19/15 11:36:47 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#6981   Thanks, FM! Are you still enjoying yourself ducruacuteo11 03/26/15 07:12:11 PM
#6980   Arghh!!!! I am too old for this BS. ducruacuteo11 03/26/15 07:11:29 PM
#6979   You have to paste it in between the Foxwoods Man 03/26/15 06:07:26 PM
#6978   stockcharts.com/h-sc/ui ducruacuteo11 03/26/15 06:01:34 PM
#6977   Right click on the image (chart)...choose "save image Foxwoods Man 03/26/15 04:55:17 PM
#6976   Silly question but how do I cut and ducruacuteo11 03/26/15 04:51:36 PM
#6975   Well, at least on the daily chart, the ducruacuteo11 03/26/15 04:41:38 PM
#6974   On your first point, I think the author ducruacuteo11 03/26/15 04:39:20 PM
#6973   a couple of issues with the article: maverick1856 03/25/15 07:33:51 PM
#6972   Mav, Here is the link to the seeking alpha ducruacuteo11 03/25/15 06:22:20 PM
#6971   short interest has decreased substantially.... maverick1856 03/25/15 10:03:22 AM
#6970   Boy you are on top of all this. Doc Hollywood 03/25/15 09:04:17 AM
#6969   the arbitration hearing is scheduled for May 4th... maverick1856 03/25/15 09:01:03 AM
#6968   Thanks for all that information. Hopefully these slow Doc Hollywood 03/25/15 08:56:57 AM
#6967   Here's an actual summary quote from yesterday's trading: Foxwoods Man 03/25/15 08:53:57 AM
#6966   generally you will see an increase over a maverick1856 03/25/15 08:27:32 AM
#6965   Since I am new to this stock, does Doc Hollywood 03/25/15 08:03:24 AM
#6964   Thanks. I did misunderstand his question. Doc Hollywood 03/25/15 08:01:35 AM
#6963   Cel-Sci Corp. Common (CVM) mick 03/24/15 06:10:37 PM
#6962   yes maverick1856 03/24/15 04:26:04 PM
#6961   IMO the IHUB site is arguably the worst tprosuper 03/24/15 04:16:15 PM
#6960   I think he was referring to the Ihub Foxwoods Man 03/24/15 04:08:40 PM
#6959   I assume you meant next Wed/Thurs Foxwoods Man 03/24/15 04:07:08 PM
#6958   the next expected news will be on Wed/Thurs maverick1856 03/24/15 03:21:41 PM
#6957   As always a stock is priced with all Doc Hollywood 03/24/15 02:33:10 PM
#6956   doc, why does pps always say na da mick 03/24/15 02:14:39 PM
#6955   looks like the end of month run is maverick1856 03/24/15 01:31:57 PM
#6954   Stock and warrants down again today. Not much Doc Hollywood 03/23/15 03:45:12 PM
#6953   Readin' todays paper and they have article Turney 03/22/15 11:24:49 AM
#6952   I agree, although the risk vs return might tprosuper 03/21/15 01:14:22 PM
#6951   Correct...assuming that $1.60 happens right before expiration. Otherwise Foxwoods Man 03/21/15 08:32:06 AM
#6950   If I am thinking straight, warrants purchased today,(CVM/WS) tprosuper 03/21/15 12:15:08 AM
#6949   20 years ago, Biogen was trading for around maverick1856 03/20/15 11:49:37 PM
#6948   With warrants the trading volume is mostly small. Doc Hollywood 03/20/15 07:29:26 PM
#6947   I tried all day to get 25K warrants ducruacuteo11 03/20/15 04:43:41 PM
#6946   I have 13 more years to go so ducruacuteo11 03/20/15 04:41:51 PM
#6945   don't forget that there are 20m warrants out maverick1856 03/20/15 03:58:14 PM
#6944   Since I am retired 3 years to wait Doc Hollywood 03/20/15 02:43:58 PM
#6943   I am hoping so or more but, for ducruacuteo11 03/20/15 02:02:30 PM
#6942   That was me. Seriously! I put ducruacuteo11 03/20/15 01:41:04 PM
#6941   Very good chance there is a settlement... maverick1856 03/20/15 01:39:49 PM
#6940   You got it. Beer in around Oct ducruacuteo11 03/20/15 01:37:08 PM
#6939   Warrants are not trading much either but there Doc Hollywood 03/20/15 11:03:34 AM
#6938   I don't mind the down day today. This tprosuper 03/20/15 11:01:40 AM
#6937   To say trading is slow today would be Doc Hollywood 03/20/15 10:43:26 AM
#6936   Good article and it give a timeline for Foxwoods Man 03/20/15 08:42:33 AM
#6935   Are you vacationing or do you actually live ducruacuteo11 03/19/15 07:58:01 PM
#6934   Once I convert the warrants to stocks, even ducruacuteo11 03/19/15 07:21:29 PM
#6933   Ummmm..full disclosure. It has been a warm, sunny Foxwoods Man 03/19/15 06:46:32 PM
#6932   So I have a question for you about ducruacuteo11 03/19/15 06:38:51 PM
PostSubject